# Lin Xu

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/lin-xu-4/

## Facts

| Field | Value |
| --- | --- |
| Citations | 27,345 |
| Field | Lung Cancer Diagnosis and Treatment |
| h-index | 74 |
| i10-index | 360 |
| Last Known Institution | Guangdong Pharmaceutical University |
| OpenAlex ID | https://openalex.org/A5100695788 |
| ORCID iD | https://orcid.org/0000-0002-2153-4840 |
| Works | 730 |

## Researcher papers

- [Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study](https://scholariq.org/papers/gefitinib-versus-vinorelbine-plus-cisplatin-as-adjuvant-treatment-for-stage-ii/)
- [A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese](https://scholariq.org/papers/a-genome-wide-association-study-identifies-two-new-lung-cancer-susceptibility/)
- [Early versus delayed administration of norepinephrine in patients with septic shock](https://scholariq.org/papers/early-versus-delayed-administration-of-norepinephrine-in-patients-with-septic/)
- [Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer](https://scholariq.org/papers/genomic-landscape-survey-identifies-srsf1-as-a-key-oncodriver-in-small-cell-lung/)
- [Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial](https://scholariq.org/papers/gefitinib-versus-vinorelbine-plus-cisplatin-as-adjuvant-treatment-for-stage-ii-2/)
- [Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 <i>EGFR</i>-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study](https://scholariq.org/papers/erlotinib-versus-gemcitabine-plus-cisplatin-as-neoadjuvant-treatment-of-stage/)
- [Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients](https://scholariq.org/papers/comprehensive-genomic-and-immunological-characterization-of-chinese-non-small/)

## Researcher topics

- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [RNA modifications and cancer](https://scholariq.org/topics/rna-modifications-and-cancer/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Cancer-related molecular mechanisms research](https://scholariq.org/topics/cancer-related-molecular-mechanisms-research/)

## Researcher university

- [Guangdong Pharmaceutical University](https://scholariq.org/institutions/guangdong-pharmaceutical-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.